key: cord-0982678-r99924c9 authors: Rozen-Zvi, Benaya; Yahav, Dafna; Agur, Timna; Zingerman, Boris; Ben-Zvi, Haim; Atamna, Alaa; Tau, Noam; Mashraki, Tiki; Nesher, Eviatar; Rahamimov, Ruth title: Antibody response to mRNA SARS-CoV-2 vaccine among kidney transplant recipients – Prospective cohort study date: 2021-05-03 journal: Clin Microbiol Infect DOI: 10.1016/j.cmi.2021.04.028 sha: fdc11d53e7e9901b09e9233606696e178b78b521 doc_id: 982678 cord_uid: r99924c9 OBJECTIVES: We aimed to evaluate rates of antibody response to mRNA SARS-CoV-2 vaccine among kidney transplant recipients, and to identify factors associated with reduced immunogenicity. METHODS: A prospective cohort study including consecutive kidney transplant recipients in a single referral transplant center. Participants were tested for anti-spike (anti-S) antibodies 2-4 weeks following second vaccine dose. Primary outcome was rate of seropositivity. Univariate and multivariate analyses were conducted to identify factors associated with seropositivity. RESULTS: Of 308 kidney transplant recipients included, only 112 (36.4%) tested positive for anti-S antibodies 2-4 weeks after receiving the second dose of BNT162b2 vaccine. Median antibody titer was 15.5 AU/mL (interquartile range [IQR] 3.5-163.6). Factors associated with antibody response were higher estimated glomerular filtration rate (eGFR) (odds ratio [OR] 1.025 per ml/min/1.73m(2), 95% confidence interval [CI] 1.014 - 1.037, p<0.001), lower mycophenolic acid dose (OR 2.347 per 360 mg decrease, 95% CI 1.782 - 3.089, p<0.001), younger age (OR 1.032 per year decrease, 95% CI 1.015 - 1.05, p<0.001) and lower calcineurin inhibitors (CNI) blood level (OR 1.987, 95% CI 1.146 - 3.443, p=0.014). No serious adverse events to the vaccine were reported. CONCLUSIONS: Kidney transplant recipients demonstrated inadequate antibody response to mRNA SARS-CoV-2 vaccination. Immunosuppression level was a significant factor in this response. Strategies to improve immunogenicity should be examined in future studies. High efficacy of the mRNA-based BNT162b2 vaccine against SARS-CoV-2 was demonstrated in both a large clinical trial and real-life data in the general population. (1) Response to vaccination among solid organ transplant recipients is expected to be diminished, (2) however has not been yet evaluated for the BNT162b2 vaccine. Current guidelines recommend vaccinating transplant candidates and recipients against SARS-CoV-2, despite lack of data regarding efficacy in these populations. (3) To assess immunogenicity to the vaccine among kidney transplant recipients, we prospectively evaluated antibody response among recipients in a single referral center in Israel, 2-4 weeks after receiving the second dose of BNT162b2. We hypothesized that transplant recipients will develop sub-optimal response to vaccine, correlated with the degree of their immunosuppression. We included adult kidney transplant recipients who were vaccinated with 2 doses BNT162b2 vaccine, 21 days apart, and followed at the Rabin Medical Center (RMC) kidney transplantation follow-up clinic between February 8 th to 28 th 2021. Consenting recipients were scheduled for a study visit 2-4 weeks after receiving the second vaccine dose and were followed for up to 6 weeks. The study was approved by the ethics committee of RMC. Data were collected including demographic data, adverse events to the vaccine, and immunosuppressive medication regimen. Blood samples were collected for anti-spike (anti-S) SARS-CoV-2 antibodies were collected during the visit. SARS-CoV-2 IgG II Quant (Abbott©) assay was used for quantitative measurement of IgG antibodies against the spike protein of SARS-CoV-2. Positive test was considered if IgG is 50 AU/mL and above. (4) Tacrolimus or cyclosporine blood level, and creatinine values were collected as well. Renal function was J o u r n a l P r e -p r o o f calculated using the chronic kidney disease epidemiology collaboration (CKD-EPI) equation. The primary outcome was rate of seropositivity for anti-S antibodies. Univariate and multivariate logistic regression analyses were performed to explore predictors of seropositivity. Statistically significant co-variates were tested for colinearity. Linear regression was conducted to evaluate factors associated with higher log transformed antibody titer. We included 308 consenting kidney transplant recipients. For baseline characteristic of participants and immunosuppressive drugs see disease, all were in the seronegative group. One had mild disease, two had severe disease, and one patient had critical illness and died in-hospital. Seropositivity rates of kidney transplant recipients to current BNT162b2 vaccine schedule are low, less than 40% in our cohort of 308 fully vaccinated recipients. Factors associated with seropositivity included younger age, higher eGFR (representing better renal function), and reduced immunosuppression (including lower dose of anti-metabolites, lower blood levels of CNI, and no use of mTOR). Similar low antibody response to mRNA COVID-19 vaccines among kidney transplant recipients was recently reported following one vaccine dose in a cohort from the US. Older age and use of anti-metabolite maintenance were significantly associated with seronegativity in this study, in line with our results. (5) Sub-optimal antibody response to other vaccines has also been previously reported among solid organ transplant recipients compared to healthy subjects. (2,6,7) Factors associated with this reduced response included use of tacrolimus as well as mycophenolic acid, the latter inhibits B-cell function and has been documented to influence antibody response to influenza vaccine depending on dose. (7, 8) Chronic kidney disease is associated with impaired innate and adaptive immunity, and inadequate antibody production after vaccination has been reported in this population. (9) A trend for lower rate of antibody response was observed in our cohort among recipients vaccinated during the first three months following transplantation; and J o u r n a l P r e -p r o o f among recipients treated with high dose corticosteroids or rituximab. Numbers were too small however to draw conclusions. Though the correlation between antibody levels after vaccination and clinical protection has not yet been proven, evidence is accumulating to support antibody response as a potential correlate of disease protection. (10) In addition, using SARS-CoV-2 IgG II Quant (Abbott©) assay in non-immunocompromised hemodialysis patients, we found ~90% seropositivity. (11) Our study limitations include lack of cellular immunity testing and/or neutralizing antibody testing. As maintenance immunosuppressive therapy for prevention of organ rejection is aimed at T-cell suppression, reduced T-cell response to vaccination among kidney transplant recipients could be expected, though this is yet to be evaluated in future studies. Regarding neutralizing antibody testing, strong correlation has been reported between anti-S antibody titers and neutralization antibody levels following BNT162b2 vaccine. (12) Several strategies have been suggested in order to improve immunogenicity in response to BNT162b2. These include a third booster dose of BNT162b2, (13) serology-based vaccine dosing, (14) BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting Serologic vaccination response after solid organ transplantation: a systematic review American Society of Transplantation COVID-19 Vaccination Guidance Abbott laboratories. SARS-CoV-2 IgG II Quant Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients Decreased antibody response to influenza vaccination in kidney transplant recipients: a prospective cohort study Immunogenicity and Safety of the 9-Valent Human Papillomavirus Vaccine in Solid Organ Transplant Recipients and Adults Infected With Human Immunodeficiency Virus (HIV) A Double-Blind, Randomized Trial of High-Dose vs Standard-Dose Influenza Vaccine in Adult Solid-Organ Transplant Recipients Current Knowledge of Vaccinations in Chronic Kidney Disease Patients Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection Antibody response to mRNA SARS-CoV-2 vaccine among dialysis patients -a prospectivecohort study Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. The Lancet Could mixing COVID vaccines boost immune response? Nature